Kenneth Widder

Nov 19, 2014

Kenneth Widder has joined Quidel’s board, expanding the company’s board to eight members. Widder has more than 30 years of experience with biomedical companies and has been a general partner with Latterell Venture Partners since 2007. He also serves on the board of Evoke Pharma, Mertiage Pharma, and Naurex.

Breaking News

Biogenes Technologies Raises $5.7M in Series A Round
Guardant Health Nabs FDA Approval for Liquid Biopsy CDx With Menarini Breast Cancer Drug
Top Five Articles on GenomeWeb Last Week: Guardant Health Layoffs, Ultima Genomics Use, More
New Products Posted to GenomeWeb: Qiagen, Thermo Fisher, Bionano Genomics, BillionToOne, More
People in the News at Illumina Ventures, Element Biosciences, Epigenomics, Exagen, More

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.